Cargando…
Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
BACKGROUND: We determined the risk thresholds above which statin use would be more likely to provide a net benefit for people over the age of 75 years without history of cardiovascular disease (CVD). METHODS: An exponential model was used to estimate the differences in expected benefit and harms in...
Autores principales: | Yebyo, Henock G., Aschmann, Hélène E., Menges, Dominik, Boyd, Cynthia M., Puhan, Milo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764041/ https://www.ncbi.nlm.nih.gov/pubmed/31598209 http://dx.doi.org/10.1177/2040622319877745 |
Ejemplares similares
-
Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020) -
Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018) -
Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023) -
Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022) -
Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)